Clinical trials: Oncologic
Chronic Lymphocytic Leukemia
A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy
This was an open-label, non-randomized, multicenter, Phase 2 study evaluating the efficacy and safety of ABT-199 in 127 participants with relapsed or refractory chronic lymphocytic leukemia (CLL) after B-cell receptor signaling…
- Trial name
- NCT02141282
- Testing
- Venetoclax
- Where
- 15 sites in United States
- Volunteers
- 127 people
- Sponsor
- AbbVie
Prostate Cancer
FACBC Prostate Therapy Response
The purpose of this study is to assess if using anti-1-amino-3-[18F]fluorocyclobutane-1-carboxylic acid (FACBC or fluciclovine) PET scan will be useful in determining if participants are responding to chemotherapy treatment.
- Trial name
- NCT02830880
- Testing
- FACBC PET-CT, MRI, CT, or Bone Scan
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Emory University
Cancer, Carcinoma
PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)
To estimate the effect of second-line panitumumab monotherapy on objective response in patients with metastatic or recurrent squamous cell carcinoma of head and neck (SCCHN).
- Conditions
- Cancer, Carcinoma, Head and Neck Cancer, Metastases
- Trial name
- NCT00446446
- Testing
- Panitumumab
- Volunteers
- 52 people
- Sponsor
- Amgen
Leukemia
Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia
RATIONALE: Giving chemotherapy before a donor stem cell transplant using stem cells that closely match the patient's stem cells, helps stop the growth of cancer cells.
- Trial name
- NCT00553202
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- 52 sites in United States, Canada
- Volunteers
- 158 people
- Sponsor
- Children's Oncology Group
Metastatic Renal Cell Carcinoma (mRCC)
Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments
The study aims to assess clinical outcomes in mRCC patients treated with sunitinib in second-line following IO therapy in real world clinical practices.
- Trial name
- NCT04175262
- Testing
- sunitinib
- Where
- Canada
- Volunteers
- 102 people
- Sponsor
- Pfizer
Pheochromocytoma, Paraganglioma
A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors
This is an ongoing prospective Phase II clinical trial evaluating the efficacy of 131I-MIBG for the treatment of patients with metastatic or unresectable pheochromocytoma and related tumors.
- Trial name
- NCT01413503
- Testing
- 131I-MIBG
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Francisco
Metastatic Pancreatic Cancer
BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
A standard treatment for your cancer is called FOLFIRINOX (this utilizes the FDA approved chemotherapy drugs fluorouracil, leucovorin, oxaliplatin and irinotecan).
- Trial name
- NCT02080221
- Testing
- FOLFOXA
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Brown University
Solid Tumours
Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney Function
This is a 2-part study in patients with advanced solid tumours. Part A will investigate the PK of olaparib in patients with mild or moderate renal impairment compared to patients with normal renal function; Part B will allow…
- Trial name
- NCT01894256
- Testing
- Olaparib tablet dosing
- Where
- 13 sites in Belgium, Denmark and 3 more
- Volunteers
- 56 people
- Sponsor
- AstraZeneca
Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer
Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)
This is a 2 part study in patients with EGFRm+ non small cell lung cancer (NSCLC), whose disease has progressed on an EGFRm TKI, who are refractory or resistant to standard therapy.
- Trial name
- NCT02157883
- Testing
- Pharmacokinetic sampling, AZD9291, Itraconazole
- Where
- 16 sites in United States, Belgium and 4 more
- Volunteers
- 39 people
- Sponsor
- AstraZeneca
Pancreatic Cancer
Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients
This is a Phase 2, multicenter, open-label, 3-arm, randomized, parallel group study to evaluate the efficacy and safety of TTX-030 with or without budigalimab in combination with chemotherapy (gemcitabine + nab-paclitaxel) in…
- Trial name
- NCT06119217
- Testing
- TTX-030, nab-paclitaxel and gemcitabine, TTX-030, budigalimab, nab-paclitaxel and gemcitabine, Nab-Paclitaxel and gemcitabine
- Where
- 64 sites in United States, Australia and 5 more
- Volunteers
- 194 people
- Sponsor
- Trishula Therapeutics, Inc.
Infection
Community Central Line Infection Prevention Trial
The overall goal of this Community Central Line Infection Prevention (CCLIP) trial, supported by grant R01 HS022870 from the Agency for Healthcare Research and Quality, is to determine whether use of a promising new intervention…
- Trial name
- CCLIP (NCT02351258)
- Testing
- 70% Isopropyl alcohol embedded caps, Usual Care
- Where
- 16 sites in United States
- Volunteers
- 16 people
- Sponsor
- Johns Hopkins University
Carcinoma, Renal Cell
Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.
Research Questions: To understand the clinical outcomes of patients treated with sunitinib in first line and axitinib in second line in a real world setting as therapies for metastatic and/or advanced renal cell carcinoma (mRCC).
- Trial name
- NCT04033991
- Testing
- Sunitinib, Axitinib
- Where
- United Kingdom
- Volunteers
- 684 people
- Sponsor
- Pfizer
Cervical Cancer, Uterine Endometrial Cancer
Implementation of a Rapid Recovery Program in Gynecologic Oncology Surgery: A Pilot Study
Over 600,000 hysterectomies are performed annually in the United States. Despite increasing use of less invasive approaches, the majority of hysterectomies are still performed via traditional laparotomy, which can be associated…
- Conditions
- Cervical Cancer, Uterine Endometrial Cancer, Ovarian Cancer
- Trial name
- NCT01705288
- Testing
- Laparotomy, intravenous narcotics, standard anesthesia
- Where
- United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Masonic Cancer Center, University of Minnesota
Bone Marrow Transplantation, Distress
Massage for Pediatric Oncology
Undergoing bone marrow transplantation (BMT) is associated with a high level of distress for patients and caregivers. Clinical research studies have reported benefits from massage for a) oncology patients, b) children, c) adults…
- Trial name
- NCT00843180
- Testing
- massage
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of California, San Francisco
Clostridium Difficile Infection, Hematologic Diseases
Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients
This study will randomized hematology oncology patients with active diarrhea and a NAAT positive/toxin EIA negative to either 14 days of oral vancomycin capsules or placebo.
- Conditions
- Clostridium Difficile Infection, Hematologic Diseases, Bone Marrow Transplant, Oncologic Disorders
- Trial name
- NCT03030248
- Testing
- Vancomycin Oral Capsule
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Medical College of Wisconsin
Oncology
Study of SUPLEXA in Patients With Metastatic Solid Tumours and Haematologic Malignancies
This Phase 1, first-in-human (FIH), open-label study is designed to assess the safety, tolerability, and preliminary clinical efficacy of repeated intravenous (IV) infusions of SUPLEXA monotherapy in subjects with measurable…
- Trial name
- NCT05237206
- Testing
- SUPLEXA
- Where
- 3 sites in Australia
- Volunteers
- 46 people
- Sponsor
- Alloplex Biotherapeutics Inc
Non-small Cell Lung Cancer, Small Cell Lung Cancer
Early Palliative Care in Advanced Lung and Gastrointestinal Malignancies
The purpose of this study is to compare two types of care - standard oncology care and standard oncology care with early palliative care (started soon after diagnosis) to see which is better for improving the experience of…
- Conditions
- Non-small Cell Lung Cancer, Small Cell Lung Cancer, Mesothelioma, Esophageal Cancer
- Trial name
- NCT01401907
- Testing
- early palliative care
- Where
- United States
- Volunteers
- 351 people
- Sponsor
- Massachusetts General Hospital
Solid Tumor, Adult
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
This is a phase 1/1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive…
- Trial name
- NCT04306900
- Testing
- TTX-030, budigalimab and mFOLFOX6, TTX-030, budigalimab and docetaxel, TTX-030 and mFOLFOX6
- Where
- 32 sites in United States, South Korea
- Volunteers
- 185 people
- Sponsor
- Trishula Therapeutics, Inc.
Solid Tumor, Lymphoma
TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
This is a phase 1/1b study of TTX-030, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive adenosine, which may change the…
- Trial name
- NCT03884556
- Testing
- TTX-030, Pembrolizumab, Gemcitabine
- Where
- 16 sites in United States
- Volunteers
- 56 people
- Sponsor
- Trishula Therapeutics, Inc.
Postoperative Complications, Obesity
Negative Pressure Wound Therapy in Obese Gynecologic Oncology Patients
The purpose of the study is to test whether the use of a new wound closure technique can decrease the rates of wound complications in obese cancer patients.
- Conditions
- Postoperative Complications, Obesity, Gynecologic Neoplasms
- Trial name
- NCT02309944
- Testing
- Standard Wound Closure, Prevena™ Incision Management System
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Masonic Cancer Center, University of Minnesota